New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO
Abraxis BioScience, Inc, an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be presented from studies which highlight the potential utility of ABRAXANE (ABI-007) as a single-agent and in combination for the treatment of breast, lung and ovarian cancers.
This entry was posted on Wednesday, May 30th, 2007 at 8:03 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.